2. Signaling Pathways
  3. Epigenetics
  4. Histone Methyltransferase
  5. PRMT5 Isoform
  6. PRMT5 Inhibitor

PRMT5 Inhibitor

PRMT5 Inhibitors (27):

Cat. No. Product Name Effect Purity
  • HY-101563
    GSK3326595
    		Inhibitor 99.97%
    GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma.
  • HY-101564
    Onametostat
    		Inhibitor 99.79%
    Onametostat (JNJ-64619178) is a selective, orally active and pseudo-irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC50 of 0.14 nM. Onametostat has potent activity in lung cancer.
  • HY-139611
    MRTX-1719
    		Inhibitor 99.40%
    MRTX-1719 is a potent, orally active, selective PRMT5•MTA complex inhibitor, with IC50 of 3.6 and 20.5 nM for PRMT5•MTA and PRMT5. MRTX-1719 binds to the PRMT5•MTA complex, with KD value of 0.14 pM. MRTX-1719 shows antineoplastic activity in vitro and in vivo, and can be used for cancer study.
  • HY-100235
    GSK591
    		Inhibitor 99.87%
    GSK591 (EPZ015866) is a potent and selective inhibitor of protein methyltransferase 5 (PRMT5) with an IC50 of 4 nM.
  • HY-107777
    LLY-283
    		Inhibitor 99.22%
    LLY-283 is a potent, selective and oral protein arginine methyltransferase 5 (PRMT5) inhibitor, with an IC50 of 22 nM and a Kd of 6 nM for PRMT5:MEP50 complex, and shows antitumor activity.
  • HY-Q36691
    PRMT5-IN-30
    		Inhibitor
    PRMT5-IN-30 (compound 17) is a potent and selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC50 of 0.33 μM and a Kd of 0.987 μM. PRMT5-IN-30 exhibits a broad selectivity against a panel of other methyltransferases. PRMT5-IN-30 inhibits PRMT5 mediated SmD3 methylation.
  • HY-161334
    CARM1-IN-4
    		Inhibitor
    CARM1-IN-4 (compound 11f) is a potent CARM1 inhibitor with IC50s of 9 nM and 56 nM for CARM1 and PRMT1, respectively. CARM1-IN-4 displays significant anti-proliferative effects on colorectal cancer cell lines. CARM1-IN-4 effectively inhibits the methyltransferase activity of CARM1 and prevents methylation of downstream proteins. CARM1-IN-4 induces apoptosis and shows antitumor activity.
  • HY-162230
    PRMT5-IN-33
    		Inhibitor
    PRMT5-IN-33 (compound A8) is a selective, SAM-competitve PRMT5 inhibitors with IC50 of 10.9 nM. PRMT5-IN-33 induces apoptosis and inhibits proliferation of cells Z-138 and MOLM-13. PRMT5-IN-33 exhibits an antitumor activity.
  • HY-148419
    TNG908
    		Inhibitor 98.89%
    TNG908 is a MTAP synergistic PRMT5 inhibitor. TNG908 crosses the blood-brain barrier and is orally active. TNG908 could be used in cancer research.
  • HY-138684
    MRTX9768
    		Inhibitor 99.60%
    MRTX9768 is a potent, selective, orally active, first-in-class PRMT5-MTA complex inhibitor.
  • HY-124131
    DS-437
    		Inhibitor 98.00%
    DS-437 is a dual PRMT5/7 inhibitor (IC50s of PRMT5/7=6 μM). DS-437 is selective for PRMT5 and PRMT7 over 29 other human protein-, DNA-, and RNA-methyltransferases. DS-437 is a S-adenosylmethionine (SAM)-competitive inhibitor of PRMT5. DS-437 also inhibits DNMT3A and DNMT3B, with IC50s of 52 and 62 μM, respectively. DS-437 inhibits the methylation of FOXP3.
  • HY-148674
    PRMT5-IN-25
    		Inhibitor 99.94%
    PRMT5-IN-25 (compound 503) is a potent PRMT5 inhibitor with an Ki value of 0.06 nM. PRMT5-IN-25 shows antiproliferative.
  • HY-132309
    BRD0639
    		Inhibitor 99.17%
    BRD0639 is a first-in-class inhibitor of the PRMT5-substrate adaptor interaction. BRD0639 is a PRMT5 binding motif (PBM)-competitive agent that can support studies of PBM dependent PRMT5 activities.
  • HY-100025A
    HLCL-61 hydrochloride
    		Inhibitor 99.95%
    HLCL-61 hydrochloride is a first-in-class inhibitor of protein arginine methyltransferase 5 (PRMT5).
  • HY-131493
    PF-06939999
    		Inhibitor 99.69%
    PF-06939999 (PRMT5-IN-3) is a PRMT5 inhibitor that exhibits synthetic lethality to tumor cells but produce few side effects combined with DNA damaging agents.
  • HY-139611C
    MRTX-1719 hydrochloride
    		Inhibitor 99.22%
    MRTX-1719 hydrochloride is a potent first-in-class selective inhibitor of the PRMT5/MTA complex, with an IC50 of less than 10 nM in PRMT5/MTA MTAPDEL SDMA cells.
  • HY-128579
    DW14800
    		Inhibitor 99.63%
    DW14800 is a protein arginine methyltransferase 5 (PRMT5) inhibitor, with an IC50 of 17 nM. DW14800 reduces H4R3me2s levels and enhances the transcription of HNF4α, but does not alter PRMT5 expression. Anti-cancer activity.
  • HY-126256
    PRMT5-IN-1
    		Inhibitor
    PRMT5 IN-1, a hemiaminal, is a potent, selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC50 of 11 nM for PRMT5/MEP50. PRMT5 IN-1 can be converted to aldehydes and react with C449 to form covalent adducts under physiological conditions.
  • HY-134883
    PRMT5-IN-4
    		Inhibitor
    PRMT5-IN-4 (compound AAA-1) is a PRMT5 inhibitor.
  • HY-141876
    PRMT5-IN-14
    		Inhibitor
    PRMT5-IN-14 is a PRMT5 inhibitor to research cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.